Theravance Biopharma (TBPH) Accumulated Expenses (2013 - 2026)

Theravance Biopharma (TBPH) has reported Accumulated Expenses for 14 consecutive years, with $8.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accumulated Expenses rose 62.09% year-over-year to $8.7 million; the TTM figure through Mar 2026 stood at $8.7 million (up 62.09% YoY), while the FY2025 annual figure was $12.6 million, up 79.4% from the prior year.
• Accumulated Expenses declined to $8.7 million in Q1 2026 per TBPH's latest filing, from $12.6 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $12.6 million in Q4 2025 and bottomed at $4.5 million in Q1 2024.
• Historically, Accumulated Expenses has averaged $7.3 million across 5 years, with a median of $7.0 million in 2022.
• On a YoY basis, Accumulated Expenses climbed as much as 727.77% in 2022 and fell as far as 52.46% in 2022.
• Theravance Biopharma's Accumulated Expenses stood at $10.3 million in 2022, then sank by 37.53% to $6.4 million in 2023, then increased by 8.94% to $7.0 million in 2024, then jumped by 79.4% to $12.6 million in 2025, then tumbled by 30.67% to $8.7 million in 2026.
• Business Quant data shows TBPH's Accumulated Expenses at $8.7 million in Q1 2026, $12.6 million in Q4 2025, and $10.3 million in Q3 2025.